Caring for Patients With EGFR-Positive Non−Small Cell Lung Cancer: An Interactive Review of New Drug Therapies Targeting Exon 20 Insertion Mutations

Caring for Patients With EGFR-Positive Non?Small Cell Lung Cancer: An Interactive Review of New Drug Therapies Targeting Exon 20 Insertion Mutations is organized by Pharmacy Times Continuing Education (PTCE).,Release date: June 14, 2022,Expiration date: June 14, 2023,Description:,Improvements in screening techniques and advancements in therapy have improved prognosis and overall survival for patients with non-small cell lung cancer (NSCLC). Identification of specific biomarkers in NSCLC such as epidermal growth factor receptor (EGFR) mutations has become central in treatment selection and expanded utilization of targeted agents including EGFR-targeted tyrosine kinase inhibitors (TKIs). However, one challenge with the use of TKIs is the development of resistance. With several EGFR-TKIs recently approved and under investigation for the treatment of NSCLC, oncology pharmacists on the multidisciplinary care team must be familiar with the characteristics of these therapies targeting exon 20 insertion mutations. While the emergence of EGFR TKIs has positively altered the landscape for EGFR-positive NSCLC, pharmacists need to be cognizant of the risks associated with these treatments and intervene to reduce these risks and improve overall outcomes. Faculty experts will review patient cases highlighting important counseling points regarding the management of adverse effects of EGFR-TKI therapy.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Explore the role of EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC) and the challenges associated with historic systemic treatment options,• Identify specific characteristics of systemic therapies targeting exon 20 insertion mutations in EGFR-positive NSCLC that specialty pharmacists should consider for patient counseling sessions,• Construct a plan for the onboarding and follow-up of a patient receiving treatment for EGFR-positive NSCLC with a novel exon 20 insertion mutation-targeting agent